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Risk for Clostridium difficile Infection After
Allogeneic Hematopoietic Cell Transplant
Remains Elevated in the Postengraftment Period
Erik R. Dubberke, MD, MSPH,1 Kimberly A. Reske, MPH,1 Margaret A. Olsen, PhD, MPH,1
Kerry M. Bommarito, PhD,MPH,1 Sondra Seiler, BA,1 Fernanda P. Silveira, MD,MS,2 TomM.Chiller, MD,MPHTM,3
John DiPersio, MD,4 Victoria J. Fraser, MD1
Background.Clostridium difficile infection (CDI) is a frequent cause of diarrhea among allogeneic hematopoietic cell transplant
(HCT) recipients. It is unknown whether risk factors for CDI vary by time posttransplant.Methods.We performed a 3-year pro-
spective cohort study of CDI in allogeneic HCTrecipients. Participants were enrolled during their transplant hospitalizations. Clinical
assessments were performed weekly during hospitalizations and for 12 weeks posttransplant, and monthly for 30 months there-
after. Data were collected through patient interviews and chart review, and included CDI diagnosis, demographics, transplant char-
acteristics, medications, infections, and outcomes. CDI cases were included if they occurred within 1 year of HCT and were
stratified by time from transplant. Multivariable logistic regression was used to determine risk factors for CDI.Results.One hun-
dred eighty-seven allogeneic HCT recipients were enrolled, including 63 (34%) patients who developed CDI. 38 (60%) CDI cases
occurred during the preengraftment period (days 0-30 post-HCT) and 25 (40%) postengraftment (day >30). Lack of any
preexisting comorbid disease was significantly associated with lower risk of CDI preengraftment (odds ratio [OR], 0.3; 95% con-
fidence interval [CI], 0.1-0.9). Relapsed underlying disease (OR, 6.7; 95%CI, 1.3-33.1), receipt of any high-risk antimicrobials (OR,
11.8; 95% CI, 2.9-47.8), and graft-versus-host disease (OR, 7.8; 95% CI, 2.0-30.2) were significant independent risk factors for
CDI postengraftment.Conclusions.A large portion of CDI cases occurred during the postengraftment period in allogeneic HCT
recipients, suggesting that surveillance for CDI should continue beyond the transplant hospitalization and preengraftment period.
Patients with continued high underlying severity of illness were at increased risk of CDI postengraftment.
(Transplantation Direct 2017;3: e145; doi: 10.1097/TXD.0000000000000662. Published online 17 March, 2017.)
C lostridium difficile infection (CDI) is a common infec-tious complication of allogeneic hematopoietic cell
transplantation (HCT), but the epidemiology, risk factors,
and outcomes of CDI in these patients are poorly understood.
Estimates of CDI incidence among allogeneic HCT recipients
vary widely, with an upper range of approximately 30%.1-9
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Many studies of CDI in this patient population are limited to
autologous HCT recipients10-13; other studies combine alloge-
neic and autologous HCT recipients1,4,14-16 and such com-
bined study results may not be applicable to allogeneic HCT
recipients alone. Incidence rates and time from transplant to
CDI may be different between autologous and allogeneic
transplant recipients,1,17,18 possibly because of differences in
immunosuppression, underlying severity of illness, or antimi-
crobial exposures between these 2 transplant populations.
Risk factors for CDI specific to HCT patients have proven
difficult to identify, likely because of study design limitations
and the ubiquity of traditional CDI risk factors among allo-
geneic HCT recipients. Several prior studies have evaluated
CDI risk factors specifically in allogeneic HCT recipi-
ents.3,5-7,9,18,19 All of these studies were retrospective and
most were limited to risk factor data collected during inpatient
hospitalizations. We previously performed a retrospective
study of CDI in allogeneic HCT at Barnes-Jewish Hospital
(BJH), and identified third-/fourth-generation cephalosporins,
diabetes, and preengraftment state as risk factors for CDI.19
Risk factors for CDI identified in other studies of HCT recipi-
ents include carbapenem use, myeloablative conditioning, and
T-cell depletion.2,6,18
Most previous studies of CDI in allogeneic HCT patients
have focused on the preengraftment period, but some studies
have reported a median time from transplant to CDI longer
than 30 days; thus, focusing on the preengraftment period
may miss a significant portion of CDI cases.1,3 Furthermore,
the ubiquity of traditional CDI risk factors among HCT pa-
tients during the preengraftment period might have limited
identification of risk factors in previously published studies,
and specific risk factors for CDImay differ by time from trans-
plant. No studies have examined the characteristics of and risk
factors for CDI among allogeneic HCT recipients stratified by
time from transplant. A better understanding of the epidemiol-
ogy of CDI is needed to prevent CDI in this highly susceptible
population. The purpose of this studywas to evaluate risk fac-
tors for and outcomes of CDI in allogeneic HCT recipients,
using a prospective study design that included outpatient as-
sessments, stratified by time from transplant.
MATERIALS AND METHODS
Study Design
This cohort studywas conducted at SitemanCancer Center,
the NCI designated comprehensive Cancer Center of BJH, a
1250-bed, tertiary care facility in St. Louis, Missouri. The
study was performed in conjunction with the Organ Trans-
plant Infection Prevention and Detection Project (OTIP) of
the Centers for Disease Control and Prevention. OTIP was a
prospective cohort study of infections in patients undergoing
allogeneic HCT or lung transplant. At BJH, only allogeneic
HCT recipients were enrolled in the OTIP study, and specific
additional data related to CDI were collected at BJH, as de-
scribed below. The study dates were April 2007 to March
2010. During the study period, the HCT ward at BJH did
not have a required neutropenic fever prophylaxis protocol,
and cefepime was the preferred agent for neutropenic fever.
Study participantswere approached to participate after admis-
sion for their allogeneic HCT hospitalization. An assessment
of each participant was performed at enrollment and weekly
during each hospitalization. After discharge, participants were
contacted by phone weekly for up to 12 weeks posttransplant.
After 12 weeks, participants were contacted monthly for
30 months post-HCT. If participants were readmitted to the
hospital, they were followed up weekly until discharge. Seven
participants had >1 HCT during the study period; for these
participants, only the first HCT was included in analyses.
The Washington University Human Research Protection Of-
fice approved this study and written informed consent was
obtained from all participants.
Data Collection
Demographic data collected at study enrollment included
age, sex, race, underlying disease status at the time of trans-
plant, comorbid diseases, type of allogeneic HCTconditioning,
prior chemotherapy/immunosuppressive therapies, and trans-
plantation history. Comorbid diseases were defined as one for
which the patient was receiving treatment or medical consulta-
tion. Other data collected at the time of transplantation in-
cluded transplant date and time, ongoing immunosuppressive
medications received, and laboratory culture and/or test results.
The weekly inpatient and outpatient assessments included pa-
tient status (home, inpatient, ICU, deceased), mechanical venti-
lation, current medications, and symptoms of infection. All
infections were reviewed by an infectious diseases physician
(E.R.D.) to determine whether the infection was probable,
confirmed, or neither. Infections were defined according to
National Nosocomial Infections Surveillance (NNIS) criteria
(now National Healthcare Safety Network).20 Graft-versus-host
disease (GVHD) was scored according to the Glucksberg
criteria.21 In addition to interviews, clinical datawere collected
prospectively from medical records when participants were
hospitalized and as available from outpatient clinic records.
CDI-Specific Data Collection
CDI was defined as a positive toxin assay for C. difficile
plus clinical symptoms consistent with CDI. Positive C. diffi-
cile toxin assay results from the BJH laboratory were collected
as part of the ongoing assessments. The BJH laboratory used
a toxin CDI test for CDI diagnosis during the study period
(Remel Xpect C. difficile Toxin A/B, Lenexa, KS). CDI-
specific data included: CDI onset date, method of diagnosis
(toxin, endoscopy, CT scan), presence of CDI symptoms (di-
arrhea, abdominal pain or distension, ileus, peritoneal signs,
fever, hypothermia, blood in stool, toxic megacolon), out-
comes (duration of illness, colectomy or other surgery for
CDI, death due to CDI), and type of, duration of, and re-
sponse to CDI therapy. Antimicrobial exposures before, dur-
ing, and after CDI were collected. Prospectively collected
medication data were supplemented with data collected elec-
tronically from the hospital’s Medical Informatics database.
CDI cases were classified by severity (mild, moderate, severe)
according to modified Common Terminology Criteria for
Adverse Events (CTCAE) criteria; details of this classification
system have been published elsewhere.19,22
Data Analysis
Participants were excluded from analyses if they had a his-
tory of CDI within the previous 60 days and/or were still re-
ceiving antimicrobial treatment for CDI at the time of their
allogeneic HCT (n = 9). For CDI cases, the CDI diagnosis
date was considered the index date. For controls (all alloge-
neic HCTrecipients who did not develop CDI), an index date
was randomly selected such that the distribution of time from
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allogeneic HCT to the index date was comparable between
cases and controls. Data analyses were stratified by time from
transplant to index date: 0 to 30 days posttransplant
(preengraftment), and 31 to 365 days posttransplant
(postengraftment). Only 2 CDI cases occurred more than
365 days posttransplant; these were considered outliers
and were excluded from analyses. Antimicrobials were classi-
fied into high risk and low risk categories based on risk of
causing CDI and our prior analysis. High risk antimicro-
bials included aminopenicillins/penicillins, cephalospo-
rins, 8-methoxyfluoroquinolones, and clindamycin23;
all other antimicrobials were considered low risk. Data such
asmedicationswere included if theyoccurredwithin the30days
before index date, including pretransplant exposures when ap-
plicable.Neutropeniawithin 48 hours before index datewas in-
cluded. Risk factors for CDI were evaluated using chi-square/
Fischer exact tests or univariate logistic regression, and logis-
tic regression was used for multivariable analyses. Because of
small sample sizes, priority for inclusion of variables into the
models was based on clinical/biological plausibility, sufficient
sample size within the variable, and univariate analyses. Var-
iables with zero cells on univariate analyses were excluded
from multivariable models. Due to the small sample size in
the postengraftment analyses, at most 3 variables could be in-
cluded at a time in multivariable models to avoid over specifi-
cation. Death within 180 days of CDI was compared by CDI
severity and time from transplant using the log-rank test. Anal-
yses were performed with SPSS, version 21.0 (IBM Corp,
Armonk, NY) and SAS version 9.2 (SAS, Cary, NC).
RESULTS
Two hundred fifty-four allogeneic HCT patients were
approached to participate in the study; 199 consented to par-
ticipate (78%), and 187 (74%) were included in analyses).
Of the 187 patients, 63 (34%) developed CDI within 1 year
TABLE 1.
Symptoms, treatment, and outcomes of CDI in allogeneic
HCT recipients
Variable
N = 63 with
CDI n (%)
CDI severitya
Mild 32 (51)
Moderate 14 (22)
Severe 17 (27)
Time from transplant to CDI (median days [range]) 23 (0-365)
CDI 0-30 d posttransplant (preengraftment) 38 (60)
CDI 31-99 d posttransplant (postengraftment) 11 (18)
CDI 100-365 d posttransplant (postengraftment) 14 (22)
Diagnosis method
Toxin assay 63 (100)
Endoscopy 1 (2)
CT scan 3 (5)
Setting onset of CDI
Inpatient 54 (86)
Outpatient 9 (14)
If outpatient, admitted for CDI? 9 (100)
Classificationa
Healthcare onset, healthcare facility-associated 50 (79)
Community onset, healthcare facility-associated 9 (14)
Indeterminate 4 (6)
Symptoms
Diarrhea severity grade (maximum during illness)b
1 26 (41)
2 19 (30)
3 11 (18)
4 7 (11)
Ileus 0
Abdominal tenderness during CDI 18 (29)
Abdominal tenderness within 48 h of CDI diagnosis 7 (11)
Peritoneal signs 1 (2)
Peritoneal signs within 48 h of CDI diagnosis 0
Abdominal distension during CDI 18 (29)
Abdominal distension within 48 h of CDI diagnosis 8 (13)
Fever during CDI 34 (54)
Fever within 48 h of CDI diagnosis 27 (43)
Hypothermia during CDI 13 (21)
Hypothermia within 48 h of CDI diagnosis 4 (6)
Blood in stool during CDI 3 (5)
Blood in stool within 48 h of CDI diagnosis 2 (3)
Toxic megacolon 0
Surgery for CDI 0
Response to CDI therapy
Responded 61 (97)
Did not respond 1 (2)
Unknown 1 (2)
Duration of CDI (median days from symptom onset to
resolution of diarrhea [range])
6 (1-51)
Days from symptom onset to response to therapy
(median [range])
5 (1-51)
Days from symptom onset to diarrhea improvement
(median [range])
4 (1-51)
Duration of CDI antimicrobial treatment (median [range]) 17 (3-83)
CDI antimicrobial treatment
Oral metronidazole alone 37 (59)
TABLE 1. (Continued)
Variable
N = 63 with
CDI n (%)
Oral and IV metronidazole 6 (10)
Oral vancomycin alone 2 (3)
Oral vancomycin and oral metronidazole 5 (8)
Oral vancomycin and IV metronidazole 3 (5)
Oral metronidazole, IV metronidazole, and oral vancomycin 9 (14)
Oral metronidazole, IV metronidazole, oral vancomycin,
and intravenous immunoglobulin
1 (2)
Died within 180 d of CDI
Mild CDIc 12 (48)
Moderate CDIc 6 (24)
Severe CDIc 7 (28)
Preengraftment CDI (0-30 d posttransplant)d 15 (60)
Postengraftment CDI (31-365 d posttransplant)d 10 (40)
CDI recurrence within 56 d of index CDI 5 (8)
a Health care onset, healthcare facility associated = CDI diagnosis≥48 hours after hospital admission;
Community onset, healthcare facility associated = CDI diagnosis as outpatient or <48 hours after ad-
mission with a discharge from a healthcare facility in the previous 4 weeks; Indeterminate = CDI di-
agnosis as outpatient or <48 hours after admission with a discharge from a healthcare facility in
the previous 4–12 weeks.28
b Per modified CTCAE criteria.19,22
c Log-rank P = 0.91; 38% of mild CDI died vs. 43% of moderate CDI and 26% of severe CDI.
d Log-rank P = 0.75; 39% of preengraftment CDI died vs. 40% of postengraftment CDI.
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of HCT and 124 (66%) did not. CDI symptoms and antimi-
crobial treatment are described in Table 1. Nine (14%) cases
were diagnosed as outpatients. No participants required sur-
gery for CDI. Ninety-seven percent of participants responded
to antimicrobial therapy, and the median time to resolution
of symptoms was 6 days. The majority of the CDI cases were
classified as mild (51%), followed by moderate (22%) and
severe (27%) according to the modified CTCAE criteria.
Therewere no significant differences in deathwithin 180 days
post-CDI between mild, moderate, and severe CDI or be-
tween preengraftment (n = 38) and postengraftment CDI
(n = 25) (Table 1; P > 0.05 for all).
Thirty-eight (60% of total) cases of CDI were diagnosed
in the preengraftment period and 81 controls had their
TABLE 2.
Risk factors for CDI preengraftment (0-30 days after transplant) (N = 119): univariate analysis and multivariable logistic
regression model
Variables CDI cases n = 38 (n [%]) Controls n = 81 (n [%]) uOR (95% CI) P aOR (95% CI) P
Age, y
18-39 9 (24) 20 (25) Reference
40-65 27 (71) 60 (74) 1.0 (0.4-2.5) 1.00
>65 2 (5) 1 (1) 4.4 (0.4-55.6) 0.25
Female 14 (37) 33 (41) 0.8 (0.4-1.9) 0.69
Comorbidities
Cardiovascular disease 15 (40) 19 (24) 2.1 (0.9-4.9) 0.07
Pulmonary disease 5 (13) 6 (7) 1.9 (0.5-6.6) 0.33
GI disease 6 (16) 6 (7) 2.3 (0.7-7.8) 0.16
Renal disease 0 (0) 3 (4) Undefined 0.55
Previous splenectomy 2 (5) 1 (1) 4.4 (0.4-50.6) 0.24
Diabetes 5 (13) 9 (11) 1.2 (0.4-3.9) 0.77
Autoimmune disease 0 0
HIV, HCV, HBV 2 (5) 4 (5) 1.1 (0.2-6.1) 1.00
Other comorbid disease 13 (34) 27 (33) 1.0 (0.5-2.3) 0.93
No comorbid disease 7 (18) 31 (38) 0.4 (0.1-0.9) 0.03 0.3 (0.1-0.9) 0.02
Neutropenic within 48 h of index date 26 (68) 47 (58) 1.6 (0.7-3.5) 0.28
Myeloablative conditioning 28 (74) 49 (61) 1.8 (0.8-4.3) 0.16 2.1 (0.9-5.0) 0.10
Related donor 13 (34) 25 (31) 1.2 (0.5-2.6) 0.72
Matched donor 37 (97) 78 (96) 1.4 (0.1-14.1) 1.00
Relapsed underlying diseasea 12 (32) 18 (22) 1.6 (0.7-3.8) 0.27
Hospitalized at index date 37 (98) 72 (89) 4.6 (0.6-37.9) 0.17
Medications in 30 d before index dateb
Any antimicrobials 35 (92) 65 (80) 2.9 (0.8-10.5) 0.12 3.2 (0.8-12.0) 0.09
Any high risk antimicrobials 27 (71) 50 (62) 1.5 (0.7-3.5) 0.32
Any low risk antimicrobials 27 (71) 55 (68) 1.2 (0.5-2.7) 0.73
Growth factors 17 (45) 34 (42) 1.1 (0.5-2.4) 0.78
Gastric acid suppressor 37 (97) 80 (99) 0.5 (0.03-7.6) 0.54
PPI 16 (42) 36 (44) 0.9 (0.4-2.0) 0.81
H2 blocker 35 (92) 76 (94) 0.8 (0.2-3.4) 0.71
Chemotherapy or total body irradiation 36 (95) 79 (98) 0.5 (0.1-3.4) 0.59
Narcotics 20 (53) 42 (52) 1.0 (0.5-2.2) 0.94
Insulin 7 (18) 16 (20) 0.9 (0.3-2.5) 0.86
Immunosuppressive/steroid 38 (100) 81 (100)
Infections within 30 d before index date
Any infection 14 (37) 34 (42) 0.8 (0.4-1.8) 0.60
BSIc 3 (8) 9 (11) 0.7 (0.2-2.7) 0.75
Pneumonia 2 (5) 3 (4) 1.4 (0.2-9.0) 0.65
Fungal infection 1 (3) 0 (0) Undefined 0.32
Viral infection 7 (18) 7 (9) 2.4 (0.8-7.4) 0.12
GVHD
Any GVHD before index date 1 (3) 1 (1) 2.2 (0.1-35.5) 0.54
Any GVHD within 7 d before index date 1 (3) 1 (1) 2.2 (0.1-35.5) 0.54
Gut GVHD within 7 d before index date 0 0
a Relapsed disease status at the time of transplant.
b Pretransplant medication exposures were included when applicable.
c All met NNIS criteria.
aOR, adjusted OR; uOR, unadjusted OR; 95% CI, 95% confidence interval.
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randomly selected index date in this time period. Only lack of
any underlying comorbid disease was significantly associated
with CDI in univariable analysis (protective effect: odds ratio
[OR], 0.4; Table 2). Cardiovascular disease was marginally
associated with increased risk of CDI in univariable anal-
ysis (Table 2). In multivariable analysis, only lack of any
underlying comorbid disease was significantly associated with
lower risk of CDI (OR, 0.3), although there was a trend for
myeloablative conditioning and receipt of any antimicrobials
in the previous 30 days to be associated with increased risk
of CDI (Table 2).
There were 25 CDI cases in the postengraftment period,
and 43 controls had their randomly selected index date dur-
ing that time (Table 3). Numerous risk factors for CDI were
identified in univariable analysis: neutropenia within 48 hours
before CDI/index, myeloablative conditioning, admitted at
index date, receipt of any antimicrobials, high risk antimicrobials,
low risk antimicrobials, gastric acid suppressor, proton pump
TABLE 3.
Risk factors for CDI postengraftment (>30 days posttransplant) (N = 68): univariate analysis and multivariable logistic
regression model
Variable CDI cases n = 25 (n [%]) Controls n = 43 (n [%]) uOR (95% CI) P-value aOR (95% CI) P
Age, y
18-39 5 (20) 12 (28) Reference
40-65 19 (76) 24 (56) 1.9 (0.6-6.3) 0.30
>65 1 (4) 7 (16) 0.3 (0.03-3.6) 0.37
Female 10 (40) 17 (40) 1.0 (0.4-2.8) 0.97
Comorbidities
Cardiovascular disease 10 (40) 7 (16) 3.4 (1.1-10.7) 0.03
Pulmonary disease 1 (4) 2 (5) 0.9 (0.1-9.9) 1.00
GI disease 3 (12) 7 (16) 0.7 (0.2-3.0) 0.74
Renal disease 0 0
Splenectomy 1 (4) 1 (2) 1.8 (0.1-29.3) 1.00
Diabetes 4 (16) 4 (9) 1.9 (0.4-8.2) 0.45
Autoimmune disease 1 (4) 0 (0) Undefined 0.37
HIV, HCV, HBV 0 (0) 1 (2) Undefined 1.00
Other comorbid disease 6 (24) 17 (40) 0.5 (0.2-1.5) 0.19
No comorbid disease 8 (32) 21 (49) 0.5 (0.2-1.4) 0.18
Neutropenic within 48 h of index date 11 (44) 0 (0) Undefined <0.01
Myeloablative conditioning 23 (92) 30 (70) 5.0 (1.0-24.3) 0.04
Related donor 10 (40) 15 (35) 1.2 (0.5-3.4) 0.67
Matched donor 25 (100) 41 (95) Undefined 0.53
Relapsed diseasea 9 (36) 7 (16) 2.9 (0.9-9.1) 0.07 6.7 (1.3-33.1) 0.02
Admitted at index date 22 (88) 4 (9) 71.5 (14.6-349.1) <0.01
Medications in 30 d before index date
Any antimicrobials 25 (100) 32 (74) Undefined <0.01
Any high-risk antimicrobials 20 (80) 14 (33) 8.3 (2.6-26.7) <0.01 11.8 (2.9-47.8) <0.01
Any low-risk antimicrobials 25 (100) 31 (72) Undefined <0.01
Growth factors 12 (48) 10 (23) 3.0 (1.1-8.8) 0.04
Gastric acid suppressor 22 (88) 20 (47) 8.4 (2.2-32.4) <0.01
PPI 13 (52) 11 (26) 3.2 (1.1-8.9) 0.03
H2 blocker 11 (44) 15 (35) 1.5 (0.5-4.0) 0.46
Chemotherapy or total body irradiation 10 (40) 10 (23) 2.2 (0.8-6.4) 0.14
Narcotic 11 (44) 11 (26) 2.3 (0.8-6.5) 0.12
Insulin 9 (36) 5 (12) 4.3 (1.2-14.8) 0.03
Immunosuppressive/steroid 23 (92) 41 (95) 0.6 (0.1-4.3) 0.62
Infections in 30 d before index date
Any infection 10 (40) 9 (21) 2.5 (0.9-7.5) 0.09
BSIb 5 (20) 2 (5) 5.1 (0.9-28.8) 0.09
Pneumonia 2 (8) 3 (7) 1.2 (0.2-7.5) 1.00
Fungal infection 2 (8) 1 (2) 3.7 (0.3-42.5) 0.55
Viral infection 2 (8) 4 (9) 0.8 (0.1-5.0) 1.00
GVHD
Any GVHD before index date 17 (68) 13 (30) 4.9 (1.7-14.2) <0.01 7.8 (2.0-30.2) <0.01
Any GVHD within 7 d before index date 8 (32) 2 (5) 9.6 (1.9-50.2) <0.01
Gut GVHD within 7 d before index date 3 (12) 0 (0) Undefined 0.05
a Relapsed disease status at the time of transplant.
b All met NNIS criteria.
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inhibitor (PPI), or insulin therapy in the previous 30 days,
any GVHD before the index date, any GVHD in the 7 days
before CDI/index date, and gut GVHD in the 7 days before
CDI/index date. Relapsed disease was associated with
marginally increased risk of CDI. The multivariable model
with best fit (Hosmer-Lemeshow P = 0.70) and strongest
clinical plausibility was receipt of high risk antimicrobials
(OR, 11.8), any GVHD before the index date (OR, 7.8),
and relapsed disease status at transplant (OR, 6.7).
DISCUSSION
This study is the first to compare risk factors for CDI in al-
logeneic HCT recipients during both the preengraftment and
postengraftment periods. This was done because these are
well defined periods of risk for infections post-HCT. The re-
sults of this study are consistent with this observation, as risk
factors for CDI varied by time from HCT. Previously pub-
lished studies of CDI in allogeneic and autologous HCT pa-
tients include a variety of follow-up periods, ranging from
30 days to 1 year.1,3,5,6,9-15,17,18,24 Kinnebrew et al6 found
that the majority of CDI cases occurred within a few days be-
fore or after HCT; however, the maximum follow-up time
was 35 days after transplant. Alonso et al10 found 81% of
CDI cases occurred within 30 days of autologous HCT. By
contrast, Willems et al,9 who evaluated CDI up to a year
post-HCT, found that the median time to CDI in their cohort
of allogeneic transplant patients was 25 days after HCT.
Chakrabarti and Alonso1,3 found median times to CDI of
38 and 33 days in their allogeneic HCT populations, respec-
tively. Similarly, we found that 60% of the CDI cases oc-
curred within 30 days of HCT, 18% occurred between days
31 and 99, and 22%of CDI cases occurred 100 ormore days
after transplant. These results, along with those of previous
investigators, indicate CDI may be more common during
the late posttransplant period than has previously been rec-
ognized.1,3,9 Post-HCT surveillance for CDI should continue
beyond 30 days to fully understand the epidemiology of CDI
in HCT patients, and to facilitate interventions to prevent
CDI at different times posttransplant.
Few specific risk factors for CDI after allogeneic HCT
have been identified previously. This may be due to the uni-
versality of common risk factors for CDI in the pre-
engraftment period, as suggested by our risk factor analysis
in the preengraftment period. Antimicrobial exposure is
widely considered the primary risk factor for CDI, but anti-
microbial use in the preengraftment period was ubiquitous
in our allogeneic HCT population; 92% of CDI cases and
80% of noncases received an antimicrobial in the previous
30 days. Other medications or procedures that could predis-
pose to CDI due to immune disruption, such as chemother-
apy and immunosuppressive or steroid use, were also
nearly universal in this allogeneic HCT population. It is likely
these variables do increase patients’ risk of CDI, but all allo-
geneic HCT patients are exposed to these types of medica-
tions. Instead, our results indicate patients’ underlying
health status pretransplant may be the primary determinant
of individual risk for CDI in the preengraftment period.
The only independent predictor of CDI in the preengraftment
period we identified was having no underlying comorbid dis-
ease, which was protective of CDI. Although underlying
health status is not a modifiable risk factor, the presence of
any comorbidity in allogeneic HCT recipients could be used
to target CDI prevention efforts. Receipt of myeloablative
conditioning pretransplant was marginally associated with
increased risk of CDI during the preengraftment period.
Kinnebrew et al6 also found that myeloablative conditioning
increased the risk of CDI. Myeloablative conditioning leads
to greater neutropenia and damage to the mucosa than
nonmyeloablative conditioning,25 resulting in increased suscep-
tibility to other infections (leading to antimicrobial exposures)
and thus increased risk ofCDI.Conversely, themucositis caused
bymyeloablative conditioning with resultant diarrheamay lead
to increased testing for C. difficile and detection of asymp-
tomatic carriage in people with diarrhea from other causes.26
In contrast, we identified numerous risk factors for CDI
during the postengraftment period. The results of univariable
and multivariable analyses indicate the patients at highest
risk for CDI in the postengraftment period were those pa-
tients with prolonged immune disruption, as indicated by
prior infections, antimicrobial use, GVHD, and neutropenia.
Reducing these patients’ exposure to the inpatient healthcare
environment may decrease their risk of CDI.27 When this ap-
proach is impossible, careful assessment of the need for and
selection of antimicrobials and gastric acid suppressants
should be performed. That a much larger proportion of pa-
tients received antimicrobials than had an infection does indi-
cate it may be possible to safely reduce or narrow the
spectrum of antimicrobial prescriptions for these patients.
These approaches have been somewhat successful at reduc-
ing rates of CDI in the general hospital population,28 al-
though CDI remains a significant problem overall.29
The relationship between GVHD and CDI is complex and
deserves additional study. Available data suggest GVHDmay
be both a risk factor and/or an outcome of CDI. In our study,
GVHD of any kind was associated with significantly in-
creased risk of CDI in the postengraftment population. Gut
GVHD was marginally associated with increased risk of
CDI in univariable analysis, but the number of individuals
with gut GVHDwas too small for the variable to be included
in the multivariable model. We have noted this relationship
between GVHD and increased risk of CDI previously at
our institution,19 as have Alonso et al and Chakrabarti
et al.1,3 Alonso found that CDI preceded GVHD in 86% of
patients, suggesting that GVHD may be an outcome of
CDI. In our analyses, we specifically examined GVHD with
onset before CDI and found GVHD to be a risk factor for
CDI in the postengraftment period. This apparent contradic-
tion can be explained by the high degree of colinearity be-
tween the conditions, particularly in the case of gut GVHD
and CDI.25 Both gut GVHD and CDI may arise from loss
of a healthy gut microbiome. Jenq et al30 reported the loss
of gastrointestinal species diversity post-HCT in patients
with GVHD, both in a mouse model and in humans. This
loss of the normal gut microbiome has serious consequences
for patients. Taur et al31 reported increased post-HCT mor-
tality in patients with low bacterial diversity in the gut
microbiome. The growing list of conditions and/or negative
patient outcomes arising from the disrupted microbiome
should give further impetus to efforts aimed at protecting pa-
tients’ normal flora, particularly through the judicious and
responsible use of antimicrobials.
Previous estimates of CDI incidence in the allogeneic HCT
population range from 12% to 30%.1,3-7,9 Our observed
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CDI incidence of 34% is slightly higher than previously pub-
lished estimates, but this may be related to differences in
study design. Kinnebrew et al6 reported an incidence of
17% within 35 days posttransplant; our CDI incidence
within 30 days of transplant was comparable at 20%. In ad-
dition, because of our prospective study design and frequent
follow-up with participants, we were able to capture outpa-
tient CDI cases among the allogeneic transplant population
that may have been missed if only inpatient data were used.
It is also possible that awareness of CDI among transplant
physicians has increased in recent years. In a previous analy-
sis of CDI in allogeneic HCTrecipients at our facility, 43%of
CDI cases were classified as having mild to moderate CDI
and 57% as having severe CDI.19 In the current study, using
the same modified CTCAE criteria for grading CDI severity,
73% of cases were classified as mild/moderate and only 27%
as severe. Heightened awareness of CDI may lead to in-
creased diagnosis of mild CDI cases that would previously
have been undetected or earlier detection of CDI that would
have become severe if diagnosis was delayed; however, trans-
plant patients are particularly prone to diarrhea due to mul-
tiple other causes (side effects of chemotherapy, radiation,
or other medications, GVHD, and so on), and the increase
in mild/moderate cases of CDI also may have led to increased
false-positive rates. Throughout the duration of the current
study and our previously published study, our clinical micro-
biology laboratory used toxin enzyme immunoassay assays
for C. difficile detection. Compared to PCR-based C. diffi-
cile detection, toxin enzyme immunoassay assays are less
likely to detect asymptomatic colonization, so detection of
asymptomatically colonized participants with diarrhea due
to unrelated causes should have been minimized.26 Analyses
of CDI incidence and outcomes in allogeneic transplant pa-
tients over time should take into consideration the diagnostic
tests used and how they may impact our understanding of
CDI epidemiology.26
There are several limitations to this study. We did not ob-
tain stool samples from participants, so we were unable to
determine whether preexisting colonization was a risk factor
for CDI or may have led to detection of asymptomatic car-
riage in subjects with diarrhea due to other causes. Data on
asymptomatic colonization preallogeneic HCT combined
with detailed, prospective clinical data could resolve the
question of whether some participants with mild CDI are in
fact asymptomatically colonized and experiencing diarrhea
due to other causes. Finally, as with many studies of risk fac-
tors for CDI among allogeneic transplant recipients, our mul-
tivariablemodels were limited by small sample size. Allogeneic
HCT recipients are a fairly small patient population, and
larger, multicenter studies are needed to alleviate this problem.
Despite these limitations, ours is one of the larger analyses of
risk factors for CDI after allogeneic HCT. In addition, due to
differences in patient risk factors for infection during the pre
versus postengraftment period, we believe it is more appropri-
ate to separate the pre and postengraftment periods to identify
risk factors for CDI.
Althoughmost previous studies have focused on CDI in the
immediate posttransplant period, our study indicates that sur-
veillance for CDI should continue into the postengraftment pe-
riod as CDI continues to impact allogeneic HCT recipients’
health postengraftment. Clinicians should carefully weigh pa-
tients’ needs for antimicrobials with the potential long-term
consequences of extensive antimicrobial use. Future studies,
particularly larger, multicenter studies, will help further eluci-
date the epidemiology of CDI in allogeneic HCT recipients
and may reveal novel strategies for CDI prevention in this
challenging patient population.
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